Cargando…

2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates

BACKGROUND: Burkholderia species can cause chronic and often severe respiratory tract infections in cystic fibrosis (CF) patients. The treatment of infections Burkholderia isolates is complicated by low cell permeability to most antimicrobial agents, presence of beta-lactamases and expression of eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Castanheira, Mariana, Shortridge, Dee, Fedler, Kelley, Carvalhaes, Cecilia G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678231/
http://dx.doi.org/10.1093/ofid/ofad500.2368
_version_ 1785150313454370816
author Castanheira, Mariana
Shortridge, Dee
Fedler, Kelley
Carvalhaes, Cecilia G
author_facet Castanheira, Mariana
Shortridge, Dee
Fedler, Kelley
Carvalhaes, Cecilia G
author_sort Castanheira, Mariana
collection PubMed
description BACKGROUND: Burkholderia species can cause chronic and often severe respiratory tract infections in cystic fibrosis (CF) patients. The treatment of infections Burkholderia isolates is complicated by low cell permeability to most antimicrobial agents, presence of beta-lactamases and expression of efflux systems. We evaluated the activity of meropenem-vaborbactam (MEV) and comparator agents tested against Burkholderia spp. isolates collected during a surveillance study. METHODS: A total of 328 Burkholderia spp. isolates were received as part of a global surveillance program from 2014 to 2022. Isolates were identified using MALDI-TOF MS and included B. cenocepacia (11), B. cepacia species complex (BCC; 268), B. gladioli (28) and B. multivorans (21). Isolates were susceptibility (S) tested by reference broth microdilution methods and CLSI interpretative criteria was applied for comparator agents for BCC isolates. Meropenem (MEM) alone breakpoints published by CLSI for BCC or EUCAST for Pseudomonas aeruginosa breakpoints were applied for MEV for comparison purposes. RESULTS: MEV (MIC(50/90), 1/2 mg/L) inhibited 95.1% of the BCC isolates at ≤4 mg/L and 97.0% at ≤8 mg/L. Trimethoprim-sulfamethoxazole (T/S), MEM and ceftazidime (CAZ) were active against 87.7%, 86.9% and 84.3% of the BCC isolates, respectively and levofloxacin and minocycline inhibited 63.4% and 82.5% of BCC isolates, respectively. Against B. multivorans (21), MEV (MIC(50/90), 0.5/2 mg/L) inhibited 95.2% of the isolates at ≤4 mg/L or ≤8 mg/L while MEM inhibited 71.4% of the isolates at ≤4 mg/L and 95.2% of the isolates at ≤8 mg/L. T/S and CAZ were active against 71.4% and 81.0% of the B. multivorans isolates. T/S MEV, MEM and CAZ were active against all 11 B. cenocepacia isolates. MEM and MEV (MIC(50/90), 0.5/2 mg/L) exhibited the same activity against 28 B. gladioli isolates. CONCLUSION: Chronic pulmonary infections caused by Burkholderia spp. isolates can lead to respiratory failure which is the primary cause of mortality and morbidity in CF patients. Despite the elevated susceptibility rates for the therapies of choice for these isolates, T/S, CAZ and MEM resistant isolates have been reported. MEV demonstrated good activity against BCC isolates that are commonly recovered from CF patients. DISCLOSURES: Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Dee Shortridge, PhD, Melinta: Grant/Research Support|Shionogi: Grant/Research Support Kelley Fedler, BS, Melinta: Grant/Research Support|Paratek: Grant/Research Support Cecilia G. Carvalhaes, MD, PhD, AbbVie: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support
format Online
Article
Text
id pubmed-10678231
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106782312023-11-27 2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates Castanheira, Mariana Shortridge, Dee Fedler, Kelley Carvalhaes, Cecilia G Open Forum Infect Dis Abstract BACKGROUND: Burkholderia species can cause chronic and often severe respiratory tract infections in cystic fibrosis (CF) patients. The treatment of infections Burkholderia isolates is complicated by low cell permeability to most antimicrobial agents, presence of beta-lactamases and expression of efflux systems. We evaluated the activity of meropenem-vaborbactam (MEV) and comparator agents tested against Burkholderia spp. isolates collected during a surveillance study. METHODS: A total of 328 Burkholderia spp. isolates were received as part of a global surveillance program from 2014 to 2022. Isolates were identified using MALDI-TOF MS and included B. cenocepacia (11), B. cepacia species complex (BCC; 268), B. gladioli (28) and B. multivorans (21). Isolates were susceptibility (S) tested by reference broth microdilution methods and CLSI interpretative criteria was applied for comparator agents for BCC isolates. Meropenem (MEM) alone breakpoints published by CLSI for BCC or EUCAST for Pseudomonas aeruginosa breakpoints were applied for MEV for comparison purposes. RESULTS: MEV (MIC(50/90), 1/2 mg/L) inhibited 95.1% of the BCC isolates at ≤4 mg/L and 97.0% at ≤8 mg/L. Trimethoprim-sulfamethoxazole (T/S), MEM and ceftazidime (CAZ) were active against 87.7%, 86.9% and 84.3% of the BCC isolates, respectively and levofloxacin and minocycline inhibited 63.4% and 82.5% of BCC isolates, respectively. Against B. multivorans (21), MEV (MIC(50/90), 0.5/2 mg/L) inhibited 95.2% of the isolates at ≤4 mg/L or ≤8 mg/L while MEM inhibited 71.4% of the isolates at ≤4 mg/L and 95.2% of the isolates at ≤8 mg/L. T/S and CAZ were active against 71.4% and 81.0% of the B. multivorans isolates. T/S MEV, MEM and CAZ were active against all 11 B. cenocepacia isolates. MEM and MEV (MIC(50/90), 0.5/2 mg/L) exhibited the same activity against 28 B. gladioli isolates. CONCLUSION: Chronic pulmonary infections caused by Burkholderia spp. isolates can lead to respiratory failure which is the primary cause of mortality and morbidity in CF patients. Despite the elevated susceptibility rates for the therapies of choice for these isolates, T/S, CAZ and MEM resistant isolates have been reported. MEV demonstrated good activity against BCC isolates that are commonly recovered from CF patients. DISCLOSURES: Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Dee Shortridge, PhD, Melinta: Grant/Research Support|Shionogi: Grant/Research Support Kelley Fedler, BS, Melinta: Grant/Research Support|Paratek: Grant/Research Support Cecilia G. Carvalhaes, MD, PhD, AbbVie: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support Oxford University Press 2023-11-27 /pmc/articles/PMC10678231/ http://dx.doi.org/10.1093/ofid/ofad500.2368 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Castanheira, Mariana
Shortridge, Dee
Fedler, Kelley
Carvalhaes, Cecilia G
2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
title 2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
title_full 2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
title_fullStr 2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
title_full_unstemmed 2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
title_short 2757. Activity of meropenem-vaborbactam tested against Burkholderia species isolates
title_sort 2757. activity of meropenem-vaborbactam tested against burkholderia species isolates
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678231/
http://dx.doi.org/10.1093/ofid/ofad500.2368
work_keys_str_mv AT castanheiramariana 2757activityofmeropenemvaborbactamtestedagainstburkholderiaspeciesisolates
AT shortridgedee 2757activityofmeropenemvaborbactamtestedagainstburkholderiaspeciesisolates
AT fedlerkelley 2757activityofmeropenemvaborbactamtestedagainstburkholderiaspeciesisolates
AT carvalhaesceciliag 2757activityofmeropenemvaborbactamtestedagainstburkholderiaspeciesisolates